Sentence: Ramucirumab plus osimertinib demonstrated encouraging safety and antitumor activity in T790M-positive EGFR-mutant NSCLC .
Drug combination annotation:
[{'class': 'POS', 'spans': ['Ramucirumab', 'osimertinib'], 'is_context_needed': False}]